CMC Pharmaceuticals Announces New Advisory Board
Date: February 10, 2022
Posted by:

CMC Pharmaceuticals Announces New Advisory Board


Solon, OH: CMC Pharmaceuticals, a provider of drug product development services to the pharmaceutical and biotechnology industries, announces the formation of an Advisory Board. The group of distinguished leaders will advise CMC Pharma on continued growth with a focus on cutting-edge science, business strategy, marketing, and risk reduction. The Members possess decades of experience in government, commercial, and academic research and development with demonstrated success including several biotech start-ups.

Board Members include Drs. John Patton, Mark Prausnitz, W. Mark Saltzman, Arthur Tipton, and Larry Zeitlin. Collectively, they have published hundreds of scientific articles, are tenured at some of the country’s top universities, started up and led established biotech and pharma companies, and have served on various fellowships and boards.

The Board held its first meeting virtually on January 24, 2022. Chairman, Dr. Arthur Tipton, has worked as an advisor to CMC Pharma for several years and expressed excitement for future engagements. “This group includes some of the most accomplished leaders in the drug development space. We look forward to celebrating wins with CMC Pharma and offering valuable strategic input to help them better serve their clients,” said Dr. Tipton.

The team at CMC Pharma, led by owner and co-founder, Dr. Mike Radomsky, helps clients with their drug product development efforts, ranging from early-stage formulation and analytical methods work to commercial-stage support.

At the inaugural meeting, Dr. Radomsky presented the 3-year growth plan and projections for expansion of drug development services, revenue, and employee headcount. With the Advisory Board’s help, CMC Pharma will expand the company’s reach while targeting specific opportunities for growth in the CDMO space. “The team at CMC Pharma has many decades of technical drug development experience, fast response times, and current capacity to begin new projects,” explained Dr. Radomsky. “The formation of an Advisory Board allows us to network and strategize with academics and industry leaders, navigating new routes for expansion while continuing to use our strengths to our advantage.”

The Advisory Board plans to have its first in-person meeting mid-2022 in Cleveland, Ohio. Members include:

Art Tipton, Chairman: Dr. Tipton is an independent consultant who aids companies in developing the next generation of drug delivery products. He was part of three successful drug delivery companies, including Founder and CEO of Brookwood Pharmaceuticals, now part of Evonik. He holds 43 U.S. patents and is an elected member of the National Academy of Inventors, the College of Fellows for the American Institute of Medical and Biological Engineering, The Controlled Release Society, and the National Academy of Engineers.

John Patton: Dr. Patton spent the first 16 years of his career in academia as a lipid biochemist and marine biologist. He then left to lead the drug delivery team at Genentech in 1985. Since then, he acquired extensive experience in biotech industry drug delivery startups, where he co-founded Inhale/Nektar Therapeutics, Dance BioPharm, InCarda, and iPharma Limited. He is now the CEO of Tesio Pharmaceuticals and the founding investor of Halozyme. Dr. Patton is a Fellow of the Controlled Release Society.

Mark Prausnitz: Dr. Prausnitz is a Regent’s Professor and J. Erskine Love, Jr. Chair in Chemical and Biomolecular Engineering at the Georgia Institute of Technology. He received a BS degree from Stanford University and Ph.D from MIT, both in chemical engineering. He has published more than 300 journal articles and has co-founded seven startup companies including Micron Biomedical and Clearside Biomedical.

W. Mark Saltzman: Dr. Saltzman is an engineer and educator who has been the sole author of three textbooks and has served as a faculty member at Johns Hopkins University, Cornell University, and Yale University. He is the founding chair of Yale’s Department of Biomedical Engineering and the Head of Yale’s Jonathan Edwards College. He has been recognized for excellence in research and teaching and has been the recipient of numerous awards and has been elected a Fellow of the American Institute for Medical and Biological Engineering, the Biomedical Engineering Society, and more.

Larry Zeitlin: Dr. Zeitlin received his doctorate in Reproductive Biology from Johns Hopkins University and served as a Research Scientist at ReProtect, and a Senior Scientist at Epicyte Pharmaceuticals. He co-founded Mapp Biopharmaceutical and ZabBio, and serves as President for both companies. His career focus has been on the development of monoclonal antibody based products to address unmet public health needs in infectious disease.

For more information on CMC Pharmaceuticals and members of the advisory board, please visit


About CMC Pharmaceuticals:
CMC Pharmaceuticals is a leading provider of drug product development services and manufacturing support to the pharmaceutical and biotechnology industries. CMC Pharmaceuticals delivers its specialized scientific expertise and services including pre-formulation, formulation development, analytical development, cGMP lab services, stability and compatibility studies, manufacturing process development and consulting services to clients globally. CMC Pharmaceuticals offers decades of specialized scientific experience in the development and manufacture of a wide range of drug product types including sterile, solid, semi-solid/liquid, topical, long-acting, controlled release, and other complex dosage forms.


For Further Information Contact:

Jared Heimovitz, Marketing & BD

CMC Pharmaceuticals


Jared Heimovitz